Online inquiry

IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3054MR)

This product GTTS-WQ3054MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets PTK7 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001270398.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5754
UniProt ID Q13308
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ3054MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4447MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-734016
GTTS-WQ4561MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-936564
GTTS-WQ9514MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA J2898A
GTTS-WQ9575MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ8025MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GZ-402668
GTTS-WQ10975MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ356MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ14993MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW